The pharmacokinetics of sumatriptan and naproxen did not differ according to whether sumatriptan/naproxen sodium was administered during a migraine attack or a migraine-free period. The pharmacokinetics of 2 sumatriptan/naproxen sodium tablets administered 2 hours apart were consistent with the pharmacokinetic predictions from a single dose of the combination tablet.

The adverse-event profile of the sumatriptan/naproxen sodium combination tablet did not appear to differ from that of the individual components of the same or similar SB203580 concentration dosage strengths administered alone or in combination. In addition, the incidence of adverse events with 2 sumatriptan/naproxen sodium tablets administered 2 hours apart was lower than that with the single dose. Conclusion.— The combination tablet of sumatriptan/naproxen sodium has unique pharmacokinetic properties. The rapid absorption of sumatriptan with the delayed-release properties of naproxen sodium from sumatriptan/naproxen sodium might contribute to its therapeutic advantage over monotherapy with either component. No clinically meaningful effects of food, administration during a migraine attack, or administration of a second tablet (2 hours after initial dose) on the pharmacokinetics or safety

of sumatriptan/naproxen sodium were observed. “
“The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders that feature short duration, repetitive attacks of severe unilateral head pain accompanied by prominent ipsilateral cranial autoniomic features. The TACs likely have a strong genetic determination, most evidently demonstrated by selleck kinase inhibitor several cluster headache studies. Key insights into their pathophysiology are derived from the cranial distribution of the pain, prominence of cranial autonomic features, attack patterns,

and distinctive therapeutic responses. These aspects are explored with regard to studies of the trigeminovascular system, 上海皓元 the trigeminal-autonomic reflex, the neuroendocrine system, functional neuroimaging, and various treatments used in clinical practice. “
“A small case series is presented of preadolescent patients with indomethacin-responsive headache. Preadolescent indomethacin-responsive headache is a rare and poorly understood entity, with few published cases in the literature. Two young children had similar presentations of indomethacin-responsive headaches. Both patients experienced frequent paroxysmal episodes of sudden-onset severe frontal or temporal head pain. The events lasted seconds to minutes in duration, and varied in frequency ranging from multiple episodes per week to multiple events per day. There were no associated autonomic or migrainous symptoms, and a comprehensive work-up revealed no secondary causes for the debilitating headaches. Both patients had dramatic clinical improvement with indomethacin.